Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial…
| Price | $62.70 |
|---|---|
| Market cap | $128.07B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NYSE |
| 52-week range | 42.52-68.64 |
| Dividend (TTM) | $2.51 per share |
| Beta | 0.23 |
Explore BMY's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.